Maggie L. Shaw

However, the risk of these rare cancers is not enough to dissuade prescribing CAR T-cell therapy for CLL, explains Kerry Rogers, MD, The James.

The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

Swarup Kumar, MD, emphasizes that preparation is central to positive outcomes and includes patient education and early intervention when needed.

Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author explains.

Policy changes could have the greatest impact on transplant equity, explains hematologic oncologist Karilyn Larkin, MD.

This new study from the VHA also shows neither cytoreductive therapy nor phlebotomy clearly lowers thrombosis risk.

Despite positive data, the study authors call for prospective validation before PRO burden is incorporated into broader risk-stratification approaches.

Andrew Kuykendall, MD, lead investigator for the VERIFY trial supporting the approval, said rusfertide is used to treat erythrocytosis in polycythemia vera.

The PARADIGM trial excluded patients with NPM1 mutations, core binding factor alterations, and FLT-3–mutated disease, so the data should not apply to them.

Scheduling apheresis, manufacturing the cells, and ultimately administering the treatment can take several weeks, Madhav Seshadri, MD, explains.

Whether these findings will translate into a change in treatment guidelines remains to be seen.

Ropeginterferon alfa-2b-njft is expected to be available immediately.

In this Director’s Cut episode of Managed Care Cast, we speak with Surbhi Sidana, MD, Stanford University, on the transformation of the myeloma field.

Ninety-six percent of the study population also had confirmed chronic traumatic encephalopathy on autopsy.

This extension to smaller drugmakers addresses a gap that has increasingly drawn attention from policy watchers.

Lymphomas arise from immune system cells and can create an environment less hospitable to CAR T-cell expansion, explained Kerry Rogers, MD.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

The study authors indicated that future investigations could further facilitate clinical decision-making regarding these regimens’ effectiveness.

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered.

Institutions need to think more creatively about how they identify and elevate talent, explains Bhavana Bhatnagar, DO.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

Drugs that form the backbone of CLL therapy are also used across lymphoma subtypes, explains Adam S. Kittai, MD.

Swarup Kumar, MD, of UConn Health, says iberdomide plus dara-dex fills a niche for relapsed disease in patients who lack access to CAR T or bispecifics.

Based on these results, the investigators are extending their follow-up into adolescence.

Previous research shows that in newly diagnosed AML, CR and composite remission rates were higher for shortened regimens of venetoclax.

Previous research has tied the loosening of permit-to-purchase and concealed carry laws to increased firearm suicide rates.

Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are limiting who can access them.

The increasingly complex CLL treatment landscape will require continued real-world study to guide sequencing decisions.

The third-gen PCKS9 inhibitor was approved in December 2025 as adjunctive treatment alongside diet and exercise for adults with hypercholesterolemia.